Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
HHS-FDA Forecasted FOR-FD-25-001Description
The purpose is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults. Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.
Funding Details
- Award Floor
- $650,000.00
- Award Ceiling
- $900,000.00
- Total Estimated Funding
- Not specified
- Expected Awards
- Not specified
Key Dates
- Posted
- August 14, 2024
- Closes
- N/A
- Archive Date
- N/A
Agency Information
- Agency Name
- HHS-FDA
- Agency Code
- HHS-FDA
- Funding Instrument
- Other